|
|
Upfront Briefing
Viatris opened the wallet for Pacira: $36.50 a share in cash, a 45% premium, for an Exparel-and-Zilretta franchise that did $692M last year and has until 2030 before generics show up. Zealand and Roche matched Lilly’s amylin weight-loss number in people with diabetes, though the blood-sugar line needs some explaining, and Pfizer got Tukysa into the first-line maintenance slot. Further down, Endeavor says its IPF drug can do more than slow decline, the next PDUFA deal ring-fences cash to rehire the reviewers HHS let go, and TRexBio priced at the bottom of its range while Retension squeezed out a $45M debut. AAO opens Saturday and the World ADC Summit on Monday. Enjoy the weekend.
📌 Reminder that if you refer someone to BioBucks by Tuesday 13 October, we’ll send you our Q1–Q3 2026 M&A report and deal sheet. After that, it’s gone. Plenty of you have already claimed yours, so thank you. 🎉 Details at the bottom ...
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,765.4 |
(0.5%) |
13.2% |
| Nasdaq 100 |
30,725.8 |
(1.4%) |
21.9% |
| Russell 2000 |
2,794.1 |
0.0% |
11.4% |
| Healthcare (XLV) |
168.2 |
(0.4%) |
8.1% |
| Biotech (XBI) |
149.3 |
(0.6%) |
22.9% |
| Nasdaq Biotech (NBI) |
6,803.3 |
(1.1%) |
19.2% |
| Clinical Trials (BBC) |
43.2 |
(0.1%) |
14.9% |
|
- Biotech fell less than tech: XBI (0.6%) and the cap-weighted NBI (1.1%) against a (1.4%) Nasdaq 100, with Healthcare (XLV) off (0.4%), BBC (0.1%) nearly flat and the Russell 2000 unchanged.
- Chips set the broader tone after a Financial Times report in the afternoon that OpenAI’s annualized revenue is running about $20B below projections: Nvidia fell 2.9% and the Philadelphia semiconductor index was down as much as 4% intraday. Brent topped $107 on Gulf tanker attacks before paring to about $104 after President Trump said the U.S. would not strike Iran before the 3 November midterms, and the 10-year eased to about 5.23%.
- Market data: U.S. cash close Thursday, 8 October 2026.
The Big 3
|
1
|
Viatris to buy Pacira for $1.65B in cash
|
- Viatris agreed to buy Pacira BioSciences for $36.50 a share in cash, about $1.65B in equity value and a 45% premium to Wednesday’s close, through a tender offer it expects to close by year-end. Exparel and Zilretta did $692M in 2025 sales; Pacira booked about $746M of revenue and $177M of adjusted EBITDA in the 12 months to June.
- Why it matters: Viatris is paying roughly 9x Pacira’s trailing adjusted EBITDA for cash flows with a known expiry. Generic Exparel can enter in early 2030 under the Fresenius Kabi and Hengrui settlements, starting at a high-single-digit share of U.S. volume and rising to the 30% range within three years, and Zilretta’s patents lapse in 2031. The bet is that Viatris’s lifecycle playbook stretches that tail, with a hospital pain bundle built around its fast-acting meloxicam, which has a 27 December PDUFA date. Leerink calls the deal immediately accretive, but formulary resistance has capped Exparel’s growth, so this buys durability rather than acceleration. Funding is mostly balance-sheet cash.
- Source: Endpoints
- More: Fierce Pharma; BioPharma Dive
|
|
2
|
Zealand, Roche amylin drug matches Lilly on weight in diabetes
|
- Petrelintide, the weekly amylin analog Roche licensed from Zealand, cut weight by up to 9.2% at week 28 vs 2.0% on placebo in the 220-patient Phase 2b ZUPREME-2 trial in people with overweight or obesity and type 2 diabetes. HbA1c fell by up to 0.65% while placebo rose 0.23%, and GI-related dropouts ran 1.9% vs 1.7%. A roughly 7,000-patient Phase 3 program is already dosing.
- Why it matters: William Blair puts the roughly 7.2-point placebo-adjusted loss level with Lilly’s eloralintide in Phase 2, so amylin monotherapy is now a tie on weight and a contest on tolerability, where petrelintide’s placebo-like GI dropout rate is the pitch. Glucose is the soft spot: a 0.61-0.88 point placebo-adjusted HbA1c cut trails the 1.3-2.1 points incretin rivals post, which weakens the standalone diabetes case and points the drug toward maintenance, overweight patients and combination use. Roche paid $1.65B upfront for the asset last year, and ZUPREME-1 showed 9.8% in people without diabetes. The full dataset at an upcoming meeting should show how much the placebo arm’s HbA1c drift shaped the read.
- Source: Endpoints
- More: Fierce Biotech
|
| 3 | Pfizer’s Tukysa wins first-line HER2+ maintenance approval |
- The FDA approved Pfizer’s Tukysa (tucatinib; HER2 inhibitor) with Herceptin and Perjeta as maintenance after induction in unresectable or metastatic HER2-positive breast cancer. In the 654-patient HER2CLIMB-05 trial, median PFS was 24.9 vs 16.3 months on Herceptin and Perjeta alone (HR 0.64; 95% CI 0.51-0.80); overall survival is not yet mature.
- Why it matters: Pfizer is trying to rebuild a Seagen asset whose sales slipped to $463M in 2025 from $480M by moving it from later lines into a chemo-free maintenance slot. An 8.6-month PFS gain is a real benefit, but the label arrives after AstraZeneca and Daiichi Sankyo’s Enhertu won first-line approval with Perjeta in late 2025, so Tukysa competes for patients who start on taxane-based induction rather than for the whole front line. The safety section is the drag: serious liver injury in 3.9% of patients, one fatal case and 8% discontinuing for hepatotoxicity, which adds monitoring work for community oncologists. Pfizer also won an Ibrance label in a similar maintenance setting in June.
- Source: Fierce Pharma
- More: Pharmaceutical Executive
|
Everything Else that broke
- Trade groups say the next PDUFA deal ring-fences FDA money that can only be spent hiring and retaining reviewers, to rebuild staff lost in the HHS layoffs. — Endpoints
- Endeavor BioMedicines’ Hedgehog inhibitor taladegib met the primary endpoint of the 213-patient Phase 2b WHISTLE-PF trial in IPF, improving ppFVC vs placebo at week 24; it gave no effect size and will take a Phase 3 plan to the FDA. — Fierce Biotech
- BMS’s Zenbexus (iberdomide) with Darzalex and dexamethasone more than doubled median PFS to 42 vs 20 months against Darzalex, Velcade and dexamethasone in relapsed myeloma (Excaliber-RRMM), backing its August accelerated approval. — Fierce Pharma
- Innovent’s SYCUME (IBI311, anti-IGF-1R) met its China Phase 3 primary endpoint in inactive thyroid eye disease, with a 60.4% vs 23.5% proptosis response at week 24 (n=116, p=0.0003). — PR
- The UK pulled the authorization for Valneva’s chikungunya vaccine Ixchiq, after the FDA suspended its U.S. license in August 2025. — Endpoints
- FDA’s CDER approved nine NMEs in September, bringing 2026’s total to 45. — BioCentury
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Viatris agreed to acquire Pacira for $36.50 a share in cash (about $1.65B equity value, 45% premium) via tender offer, closing by year-end. — Fierce Pharma
- Ono paid Biohaven $80M upfront for Japan, South Korea, Taiwan and ASEAN rights to three IgG degraders led by Phase 3 Graves’ asset BHV-1300, plus a $20M milestone and a 20% profit share. — Fierce Biotech
- Theramex licensed Europe, Australia, New Zealand and Turkey rights to Asieris’ cervical precancer treatment Cevira (APL-1702, under EMA review) for $15M upfront, subject to conditions, and more than $250M in total. — Fierce Pharma
VC / Private Financings
- Multiply Labs raised a $75M Series B for robotic biologics and cell-therapy manufacturing. — Endpoints
IPOs / Follow-Ons
- TRexBio priced its IPO at $14, the bottom of its $14-16 range, for $116.7M gross (TRB-061, TNFR2 agonist, Phase 1 atopic dermatitis); Retension raised about $45M in its debut (RTN-001, Phase 2b hypertension). — Endpoints
- Iambic set terms for 9.4M shares at $15-17, about $150M gross at the midpoint, to fund IAM1363, its brain-penetrant HER2 inhibitor in Phase 1. — Fierce Biotech
Academic Corner - Lancet commentary examined what TRIUMPH-2 retatrutide data mean for obesity with type 2 diabetes. — Lancet
|
Have a great weekend. Pacira holders, enjoy the tender.
— BioBucks Team
|
|
|
